Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative ...

Processa Pharmaceuticals has dosed the first subject in its Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) to treat patients with advanced or metastatic breast cancer.

“Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type Ras metastatic colorectal cancer regardless of the primary site” In this ...

Herrmann et al. compared the safety and efficacy of gemcitabine plus capecitabine (GemCap) with that of gemcitabine monotherapy in patients with pancreatic cancer. This phase III trial included ...

In view of the patient's long progression-free survival (12.9 months), we decided to resume intramuscular octreotide (30 mg every 3 weeks) with capecitabine and liposomal doxorubicin chemotherapy ...

During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively ...